Mercedes Corina Becerra, Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis, Multidrug-Resistant | 50 | 2020 | 912 | 6.160 |
Why?
|
Antitubercular Agents | 45 | 2022 | 1320 | 3.770 |
Why?
|
Tuberculosis | 32 | 2022 | 1912 | 3.150 |
Why?
|
Tuberculosis, Pulmonary | 20 | 2023 | 810 | 2.320 |
Why?
|
Peru | 44 | 2023 | 881 | 2.200 |
Why?
|
Mycobacterium tuberculosis | 29 | 2022 | 1832 | 2.030 |
Why?
|
Contact Tracing | 12 | 2020 | 273 | 1.980 |
Why?
|
Isoniazid | 13 | 2022 | 274 | 1.870 |
Why?
|
Family Characteristics | 12 | 2020 | 1000 | 1.150 |
Why?
|
Drug Resistance, Multiple, Bacterial | 9 | 2016 | 567 | 0.870 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 3 | 2013 | 92 | 0.810 |
Why?
|
Directly Observed Therapy | 6 | 2012 | 137 | 0.740 |
Why?
|
Sputum | 11 | 2021 | 476 | 0.630 |
Why?
|
Rifampin | 6 | 2021 | 315 | 0.510 |
Why?
|
Tuberculosis, Meningeal | 1 | 2014 | 45 | 0.480 |
Why?
|
Medication Systems, Hospital | 1 | 2013 | 158 | 0.420 |
Why?
|
Child, Preschool | 29 | 2022 | 41006 | 0.380 |
Why?
|
Latent Tuberculosis | 3 | 2021 | 225 | 0.360 |
Why?
|
Remote Consultation | 1 | 2013 | 238 | 0.360 |
Why?
|
Microbial Sensitivity Tests | 7 | 2019 | 1877 | 0.360 |
Why?
|
Adolescent | 37 | 2022 | 85781 | 0.350 |
Why?
|
Pyrazinamide | 3 | 2016 | 54 | 0.330 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2026 | 0.330 |
Why?
|
Infant | 23 | 2022 | 35136 | 0.330 |
Why?
|
Family Health | 1 | 2013 | 1282 | 0.320 |
Why?
|
Mass Screening | 6 | 2022 | 5255 | 0.320 |
Why?
|
Treatment Failure | 7 | 2023 | 2618 | 0.310 |
Why?
|
Child | 35 | 2022 | 77709 | 0.310 |
Why?
|
Antibiotics, Antitubercular | 3 | 2005 | 104 | 0.300 |
Why?
|
Developing Countries | 8 | 2013 | 2815 | 0.270 |
Why?
|
Electronic Health Records | 2 | 2013 | 4468 | 0.270 |
Why?
|
National Health Programs | 4 | 2021 | 445 | 0.240 |
Why?
|
Humans | 89 | 2023 | 744343 | 0.240 |
Why?
|
Tuberculin Test | 3 | 2019 | 214 | 0.240 |
Why?
|
Pakistan | 4 | 2022 | 295 | 0.220 |
Why?
|
Primary Prevention | 2 | 2020 | 1167 | 0.220 |
Why?
|
Age Factors | 12 | 2022 | 18370 | 0.210 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2005 | 371 | 0.210 |
Why?
|
Population Surveillance | 3 | 2011 | 2616 | 0.210 |
Why?
|
Adult | 43 | 2023 | 214055 | 0.210 |
Why?
|
Ethambutol | 2 | 2016 | 60 | 0.200 |
Why?
|
Treatment Outcome | 22 | 2023 | 63114 | 0.200 |
Why?
|
Drug Resistance, Multiple | 2 | 2001 | 252 | 0.200 |
Why?
|
Young Adult | 16 | 2022 | 56430 | 0.200 |
Why?
|
Cost of Illness | 1 | 2010 | 1859 | 0.190 |
Why?
|
Female | 50 | 2022 | 380194 | 0.190 |
Why?
|
Internet | 1 | 2012 | 3064 | 0.180 |
Why?
|
Male | 48 | 2022 | 350118 | 0.180 |
Why?
|
Infant, Newborn | 10 | 2022 | 25625 | 0.180 |
Why?
|
Early Diagnosis | 2 | 2015 | 1184 | 0.180 |
Why?
|
HIV Infections | 7 | 2020 | 16718 | 0.180 |
Why?
|
Secondary Prevention | 3 | 2016 | 1530 | 0.170 |
Why?
|
Retrospective Studies | 25 | 2021 | 77449 | 0.170 |
Why?
|
Endemic Diseases | 1 | 2000 | 182 | 0.170 |
Why?
|
Economics | 1 | 2000 | 146 | 0.170 |
Why?
|
Environmental Exposure | 1 | 2013 | 4234 | 0.160 |
Why?
|
Incidence | 8 | 2019 | 20947 | 0.160 |
Why?
|
Communicable Disease Control | 3 | 2021 | 857 | 0.160 |
Why?
|
Health Services Accessibility | 5 | 2022 | 5137 | 0.150 |
Why?
|
Prevalence | 8 | 2020 | 15226 | 0.150 |
Why?
|
BCG Vaccine | 3 | 2014 | 369 | 0.150 |
Why?
|
Prospective Studies | 10 | 2021 | 53288 | 0.140 |
Why?
|
Lost to Follow-Up | 1 | 2016 | 105 | 0.130 |
Why?
|
Amidohydrolases | 1 | 2016 | 169 | 0.130 |
Why?
|
Drug Therapy, Combination | 7 | 2021 | 6489 | 0.130 |
Why?
|
Entamoebiasis | 1 | 2013 | 14 | 0.120 |
Why?
|
Protozoan Infections | 1 | 2013 | 39 | 0.120 |
Why?
|
Giardiasis | 1 | 2013 | 28 | 0.120 |
Why?
|
Amebiasis | 1 | 2013 | 34 | 0.120 |
Why?
|
Blastocystis Infections | 1 | 2013 | 16 | 0.120 |
Why?
|
Cohort Studies | 12 | 2020 | 40561 | 0.120 |
Why?
|
Genotype | 4 | 2019 | 12951 | 0.120 |
Why?
|
Drug Resistance, Bacterial | 3 | 2013 | 1035 | 0.110 |
Why?
|
Disease Progression | 2 | 2019 | 13284 | 0.110 |
Why?
|
Middle Aged | 20 | 2022 | 213383 | 0.110 |
Why?
|
Sentinel Surveillance | 1 | 2014 | 281 | 0.110 |
Why?
|
Haiti | 2 | 2013 | 553 | 0.100 |
Why?
|
Health Policy | 2 | 2017 | 2661 | 0.100 |
Why?
|
Delivery of Health Care | 2 | 2021 | 5319 | 0.100 |
Why?
|
Disease Notification | 1 | 2012 | 97 | 0.100 |
Why?
|
Electronic Prescribing | 1 | 2013 | 121 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6538 | 0.100 |
Why?
|
Analysis of Variance | 3 | 2020 | 6365 | 0.100 |
Why?
|
Public-Private Sector Partnerships | 1 | 2012 | 121 | 0.100 |
Why?
|
Comprehensive Health Care | 1 | 2012 | 127 | 0.100 |
Why?
|
Urban Health Services | 1 | 2012 | 179 | 0.100 |
Why?
|
Mutation | 4 | 2016 | 29786 | 0.100 |
Why?
|
Professional Competence | 1 | 2014 | 447 | 0.100 |
Why?
|
Likelihood Functions | 1 | 2014 | 1005 | 0.100 |
Why?
|
Computer Systems | 1 | 2012 | 483 | 0.100 |
Why?
|
Socioeconomic Factors | 3 | 2022 | 7785 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2000 | 1772 | 0.090 |
Why?
|
Information Systems | 1 | 2012 | 410 | 0.090 |
Why?
|
Geographic Information Systems | 1 | 2012 | 281 | 0.090 |
Why?
|
Time Factors | 8 | 2014 | 40075 | 0.090 |
Why?
|
Registries | 2 | 2013 | 8089 | 0.090 |
Why?
|
Community Health Services | 3 | 2011 | 650 | 0.090 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39050 | 0.090 |
Why?
|
Epidemiologic Studies | 1 | 2012 | 676 | 0.080 |
Why?
|
Program Development | 2 | 2012 | 1316 | 0.080 |
Why?
|
Public Health | 1 | 2022 | 2603 | 0.080 |
Why?
|
Tobacco Smoke Pollution | 1 | 2014 | 816 | 0.080 |
Why?
|
Risk | 3 | 2016 | 9687 | 0.080 |
Why?
|
Lesotho | 3 | 2013 | 70 | 0.080 |
Why?
|
Health Personnel | 3 | 2021 | 3218 | 0.080 |
Why?
|
Risk Factors | 13 | 2023 | 72290 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2022 | 3158 | 0.080 |
Why?
|
Russia | 3 | 2014 | 408 | 0.080 |
Why?
|
Models, Organizational | 1 | 2011 | 574 | 0.080 |
Why?
|
HIV Seronegativity | 1 | 2008 | 211 | 0.080 |
Why?
|
Genes, Bacterial | 1 | 2011 | 1079 | 0.070 |
Why?
|
Community-Acquired Infections | 1 | 2011 | 465 | 0.070 |
Why?
|
Odds Ratio | 5 | 2022 | 9849 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2013 | 1275 | 0.070 |
Why?
|
HIV Seropositivity | 1 | 2012 | 971 | 0.070 |
Why?
|
Cross Infection | 1 | 2015 | 1416 | 0.070 |
Why?
|
Program Evaluation | 2 | 2011 | 2488 | 0.070 |
Why?
|
Clinical Protocols | 4 | 2021 | 1462 | 0.070 |
Why?
|
World Health Organization | 3 | 2020 | 1318 | 0.070 |
Why?
|
Recurrence | 3 | 2016 | 8340 | 0.070 |
Why?
|
Health Education | 1 | 2012 | 1056 | 0.070 |
Why?
|
Checklist | 1 | 2012 | 833 | 0.060 |
Why?
|
Aged | 10 | 2021 | 163280 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2008 | 421 | 0.060 |
Why?
|
Streptomycin | 1 | 2004 | 69 | 0.060 |
Why?
|
Drug Resistance, Microbial | 2 | 2005 | 862 | 0.060 |
Why?
|
Drug Administration Schedule | 4 | 2016 | 4933 | 0.060 |
Why?
|
Infection Control | 1 | 2010 | 966 | 0.060 |
Why?
|
Case-Control Studies | 4 | 2015 | 21746 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2011 | 1411 | 0.060 |
Why?
|
Tuberculin | 1 | 2022 | 66 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 941 | 0.060 |
Why?
|
Public Health Administration | 1 | 2005 | 240 | 0.050 |
Why?
|
Community Health Centers | 1 | 2005 | 430 | 0.050 |
Why?
|
Feeding Behavior | 1 | 2014 | 3188 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 3923 | 0.050 |
Why?
|
Tajikistan | 1 | 2000 | 4 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2011 | 7279 | 0.050 |
Why?
|
X-Rays | 1 | 2021 | 301 | 0.050 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12354 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 4803 | 0.040 |
Why?
|
Ambulatory Care | 2 | 2008 | 2708 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 7913 | 0.040 |
Why?
|
Vulnerable Populations | 2 | 2017 | 687 | 0.040 |
Why?
|
Pregnancy | 1 | 2020 | 29144 | 0.040 |
Why?
|
Methicillin Resistance | 1 | 1999 | 198 | 0.040 |
Why?
|
Social Support | 1 | 2008 | 2118 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15540 | 0.040 |
Why?
|
Sampling Studies | 1 | 2000 | 623 | 0.040 |
Why?
|
Substance-Related Disorders | 2 | 2012 | 4258 | 0.040 |
Why?
|
Smoking | 1 | 2014 | 8987 | 0.040 |
Why?
|
Decision Making | 1 | 2011 | 3887 | 0.040 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2019 | 494 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8642 | 0.030 |
Why?
|
International Cooperation | 1 | 2003 | 1420 | 0.030 |
Why?
|
Prognosis | 1 | 2016 | 29063 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3508 | 0.030 |
Why?
|
Research Design | 2 | 2013 | 5987 | 0.030 |
Why?
|
Health Resources | 1 | 2001 | 911 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7799 | 0.030 |
Why?
|
Sex Factors | 2 | 2020 | 10397 | 0.030 |
Why?
|
Entamoeba | 1 | 2013 | 6 | 0.030 |
Why?
|
Endolimax | 1 | 2013 | 7 | 0.030 |
Why?
|
Blastocystis hominis | 1 | 2013 | 7 | 0.030 |
Why?
|
Risk Assessment | 4 | 2020 | 23338 | 0.030 |
Why?
|
Giardia lamblia | 1 | 2013 | 23 | 0.030 |
Why?
|
Cost-Benefit Analysis | 3 | 2021 | 5391 | 0.030 |
Why?
|
Genetic Fitness | 1 | 2015 | 121 | 0.030 |
Why?
|
Capreomycin | 1 | 2013 | 14 | 0.030 |
Why?
|
HIV | 1 | 2001 | 1604 | 0.030 |
Why?
|
Kanamycin | 1 | 2013 | 64 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14722 | 0.030 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2013 | 30 | 0.030 |
Why?
|
Biological Assay | 1 | 2016 | 652 | 0.030 |
Why?
|
Logistic Models | 2 | 2022 | 13408 | 0.030 |
Why?
|
Clarithromycin | 1 | 2013 | 86 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 513 | 0.030 |
Why?
|
Molecular Epidemiology | 1 | 2015 | 468 | 0.030 |
Why?
|
Latvia | 1 | 2012 | 14 | 0.030 |
Why?
|
Estonia | 1 | 2012 | 53 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2001 | 1873 | 0.030 |
Why?
|
Philippines | 1 | 2012 | 86 | 0.030 |
Why?
|
HIV Seroprevalence | 1 | 2012 | 86 | 0.030 |
Why?
|
Georgia (Republic) | 1 | 2011 | 41 | 0.030 |
Why?
|
England | 1 | 2013 | 522 | 0.030 |
Why?
|
Fluoroquinolones | 1 | 2013 | 310 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 7023 | 0.020 |
Why?
|
Drug Therapy | 1 | 2014 | 497 | 0.020 |
Why?
|
Focus Groups | 1 | 2015 | 1321 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2003 | 3610 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1439 | 0.020 |
Why?
|
Models, Theoretical | 2 | 2014 | 3589 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12245 | 0.020 |
Why?
|
Health Surveys | 1 | 2000 | 4037 | 0.020 |
Why?
|
Genetic Loci | 1 | 2019 | 2575 | 0.020 |
Why?
|
Monocytes | 1 | 2019 | 2596 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2011 | 438 | 0.020 |
Why?
|
Financing, Personal | 1 | 2011 | 308 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2015 | 2539 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2559 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2971 | 0.020 |
Why?
|
Consensus | 1 | 2015 | 2959 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2012 | 933 | 0.020 |
Why?
|
Survival Rate | 1 | 2000 | 12788 | 0.020 |
Why?
|
Education | 1 | 2008 | 543 | 0.020 |
Why?
|
Retreatment | 1 | 2006 | 610 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2011 | 1504 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2016 | 3966 | 0.010 |
Why?
|
Peroxidases | 1 | 2004 | 138 | 0.010 |
Why?
|
Aged, 80 and over | 3 | 2014 | 57776 | 0.010 |
Why?
|
Motivation | 1 | 2012 | 1971 | 0.010 |
Why?
|
Parents | 1 | 2015 | 3407 | 0.010 |
Why?
|
Oxidoreductases | 1 | 2004 | 424 | 0.010 |
Why?
|
Algorithms | 2 | 2012 | 13881 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10252 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2016 | 13989 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 12261 | 0.010 |
Why?
|
Patient Care Team | 1 | 2011 | 2531 | 0.010 |
Why?
|
Virulence | 1 | 2004 | 1333 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2012 | 3528 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5102 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 3022 | 0.010 |
Why?
|
Databases, Factual | 1 | 2013 | 7729 | 0.010 |
Why?
|
Poverty | 2 | 2001 | 2660 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2505 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2004 | 2886 | 0.010 |
Why?
|
Health Care Costs | 1 | 2011 | 3209 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10388 | 0.010 |
Why?
|
Health Planning | 1 | 1998 | 238 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15076 | 0.010 |
Why?
|
HIV-1 | 1 | 2013 | 6939 | 0.010 |
Why?
|
Morals | 1 | 1998 | 284 | 0.010 |
Why?
|
Body Mass Index | 1 | 2012 | 12720 | 0.010 |
Why?
|
Patient Compliance | 1 | 2004 | 2684 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10943 | 0.010 |
Why?
|
Rural Population | 1 | 2001 | 2210 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2004 | 3848 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 25043 | 0.010 |
Why?
|
Disease Management | 1 | 1999 | 2459 | 0.010 |
Why?
|
Mental Disorders | 1 | 2008 | 6600 | 0.000 |
Why?
|
Anti-HIV Agents | 1 | 2001 | 4256 | 0.000 |
Why?
|